According to the National Institute of Health (NIH), Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body’s center (distal). The muscle weakness usually worsens with age.
Get FREE sample copy at:
Spinal Muscular Atrophy market report also covers emerging drugs, current treatment practices, Spinal Muscular Atrophy market share of the individual therapies, current and forecasted Spinal Muscular Atrophy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Spinal Muscular Atrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Spinal Muscular Atrophy Market Key Facts
The total prevalent population of Spinal Muscular Atrophy (SMA) in the seven major markets are 19,343 cases in 2017.
As per the estimates among the EU5 countries, Germany had the highest prevalent population of Spinal Muscular Atrophy with 1,643 cases in 2017 followed by the UK and France. On the other hand, Spain had the lowest prevalence with 468 cases in 2017.
As per DelveInsight analysis, the diagnosed prevalent cases of Spinal Muscular Atrophy in the United States were found to be 11,733 in 2017.
As per the study conducted by B. Melissa et al., (2017), Spinal muscular atrophy (SMA) is the most common genetic disease resulting in death in infancy, affecting approximately 1 in 6,000 to 1 in 10,000 births. Therapies that improve neuromuscular function as well as maintain lifelong general health of people living with SMA are therefore a major priority and an unmet clinical need.
Key Benefits of Spinal Muscular Atrophy Market Report
Spinal Muscular Atrophy market report provides an in-depth analysis of Spinal Muscular Atrophy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Spinal Muscular Atrophy market report will help in developing business strategies by understanding the Spinal Muscular Atrophy Market trends & developments, key players and future market competition that will shape and drive the Spinal Muscular Atrophy market in the upcoming years.
The Spinal Muscular Atrophy market report covers Spinal Muscular Atrophy current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Spinal Muscular Atrophy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Spinal Muscular Atrophy Market
Spinal muscular atrophy (SMA) being a rare genetic neuromuscular disorder results in progressive muscle weakness and atrophy. Current management of SMA is based on supportive and multidisciplinary care with a focus on reducing complications and improving quality of life. The current market holds alternatives for symptomatic relief with curative therapy being a high unmet need. Approaches for management of Spinal Muscular Atrophy lays focus on Nutrition, Respiratory Care Assessment, Respiratory Muscle Weakness, Orthopedic Care, Rehabilitation, along with few medications.
Extensive research and development activities of pharmaceutical companies, along with rising prevalence are expected to fuel the growth of the market in the coming years.
The Spinal Muscular Atrophy market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Spinal Muscular Atrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Spinal Muscular Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Spinal Muscular Atrophy Epidemiology
The Spinal Muscular Atrophy epidemiology section covers insights about historical and current Spinal Muscular Atrophy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Spinal Muscular Atrophy Drugs Uptake and Key Market Players
The Spinal Muscular Atrophy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to get launched in the market during the study period. The analysis covers Spinal Muscular Atrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Spinal Muscular Atrophy pipeline possess multiple potential drugs in late and mid stage developments to be launched in the near future. Some of the key players developing therapies for the treatment of patients with Spinal Muscular Atrophy includes:
And many others.
Amifampridine Phosphate (Firdapse)
And few others.
Table of Content
1. Key Insights
2. Executive Summary
3. Spinal Muscular Atrophy Competitive Intelligence Analysis
4. Spinal Muscular Atrophy Market Overview at a Glance
5. Spinal Muscular Atrophy Disease Background and Overview
6. Spinal Muscular Atrophy Patient Journey
7. Spinal Muscular Atrophy Epidemiology and Patient Population
8. Spinal Muscular Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Spinal Muscular Atrophy Unmet Needs
10. Key Endpoints of Spinal Muscular Atrophy Treatment
11. Spinal Muscular Atrophy Marketed Products
12. Spinal Muscular Atrophy Emerging Therapies
13. Spinal Muscular Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Spinal Muscular Atrophy Market Outlook (7 major markets)
16. Spinal Muscular Atrophy Access and Reimbursement Overview
17. KOL Views on the Spinal Muscular Atrophy Market.
18. Spinal Muscular Atrophy Market Drivers
19. Spinal Muscular Atrophy Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Spinal Muscular Atrophy (SMA) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Spinal Muscular Atrophy (SMA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Spinal Muscular Atrophy (SMA) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Spinal Muscular Atrophy (SMA) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States